AB Science announces the implementation of a new strategy and the launch of a capital raise

AB Science announces the implementation of a new strategy and the launch of a capital raise

press release

Focus development strategy on amyotrophic surface sclerosis with the macinib platform and on the second microtubule platform and search for a partnership for non-rare indications for macinib diseases

Launching the capital increase in the context of a private placement for a maximum amount of approximately €15.0 million.

Paris, April 21, 2023, at 10 p.m

AB Science SA (“the Company” or “AB Science”, Euronext – FR0010557264 – AB) announces today the implementation of a new strategy and the launch, in support of this new strategy, of raising capital by issuing new ordinary shares to each of which will be attached to share warrants with cancellation Preferential subscription rights for shareholders, by way of private placement up to a maximum of approximately €15 million (“capital increase”).

I. Focusing the development strategy on amyotrophic surface sclerosis with the macinib platform, on the second microtubule platform and seeking partnership for non-rare indications for macinib diseases

AB Science has decided to focus its development strategy as follows:

See also  Quais são seus efeitos em nossa saúde?

You May Also Like

About the Author: Irene Alves

"Bacon ninja. Guru do álcool. Explorador orgulhoso. Ávido entusiasta da cultura pop."

Leave a Reply

Your email address will not be published. Required fields are marked *